Gravity Analytica

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

MRKR 11.26.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-12-02

Name of Upcoming Event:Citizens JMP Hematology and Oncology Summit

Full Press Release SEC Filings Our MRKR Tweets

About Gravity Analytica

Recent Filings

HOUSTON,Nov. 26, 2024(GLOBE NEWSWIRE) --Marker Therapeutics, Inc.(Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced thatJuan Vera, M.D., President and Chief Executive Officer ofMarker Therapeutics, will present at the Citizens JMP Hematology and Oncology Summit. This investor event will be held virtually onDecember 2, 2024.

Dr. Verawill present an overview of Marker’s technology and clinical developments onMonday, December 2, 2024, at11 AM EST.

Details of the presentation are as follows:

Event:	The Citizens JMP Hematology and Oncology Summit
Date:	December 2, 2024, at11 AM EST
Location:	Virtual Event
Webcast:	https://wsw.com/webcast/jmp66/register.aspx?conf=jmp66&page=mrkr&url=https://wsw.com/webcast/jmp66/mrkr/1699092

After the event, Dr. Vera’s presentation will be available for replay on the Company’s IR website underEvents & Presentations.

During the conference,Dr. Veraand members of the Marker management team will conduct one-on-one meetings with registered investors, showcasing the Company’s business and clinical development.

AboutMarker Therapeutics, Inc.Marker Therapeutics, Inc.is aHouston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. Clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic multiTAA-specific T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding fromU.S.state and federal agencies supporting cancer research.

To receive future press releases via email, please visit:https://www.markertherapeutics.com/email-alerts.

Forward-Looking StatementsThis release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials of our product candidates, including MT-601 for the treatment of patients with lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR atWWW.SEC.GOV. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.

ContactsInvestorsTIBEREND STRATEGIC ADVISORS, INC.Jonathan Nugent205-566-3026jnugent@tiberend.com

Source: Marker Therapeutics

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com